Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Single-Arm, Open-Label Trial to Evaluate the Safety, Feasibility, and Immunogenicity of Ex Vivo CRISPR-Cas9 Gene-Edited Donor Kidneys (Knockout of HLA-A, HLA-B, and CIITA) in Human Renal Transplant Recipients

NCT07053462 is registered in ClinicalTrials.gov with AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC as lead sponsor.

NCT NCT07053462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07053462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Single-Arm, Open-Label Trial to Evaluate the Safety, Feasibility, and Immunogenicity of Ex Vivo CRISPR-Cas9 Gene-Edited Donor Kidneys (Knockout of HLA-A, HLA-B, and CIITA) in Human Renal Transplant Recipients
Lead sponsor
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2025
Completion date
December 28, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease on dialysis, end stage renal disease with renal transplant, end-stage renal disease, kidney failure, kidney ischemia, kidney transplant rejection, kidney tumor